SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT02009826

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Phase 0 Clinical Protocol: A Longitudinal and Multimodal Exploratory Study to Evaluate a Neuroinflammatory Hypothesis in Patients With Schizophrenia Compared to Young Healthy Subjects

Previous research has suggested central nervous system inflammatory activity to be critically involved in disease development and progression in schizophrenia, with a complex interplay of inflammatory mechanisms leading to the development of brain abnormalities and medical symptoms related to schizophrenia. However, the mutual interactions of different inflammatory pathways and their relation to disease course have not been sufficiently studied. This study therefore aims to explore the interaction of neuroinflammatory mechanisms in patients with schizophrenia and to assess whether the inflammatory activity in schizophrenia is state-dependent and occurs mainly during psychotic episodes.

NCT02009826 Schizophrenia Psychosis
MeSH: Schizophrenia Psychotic Disorders Mental Disorders
HPO: Psychosis Schizophrenia

3 Interventions

Name: [18F]-PBR111 Positron Emission Tomography (PET)

Description: [18F]-PBR111 radioligand to assess binding to TSPO

Type: Radiation

Healthy controls Schizophrenia patients

Name: Cognitive and psychomotor tasks

Description: Cognitive and psychomotor tasks on digitizing tablet

Type: Behavioral

Healthy controls Schizophrenia patients

Name: Blood sampling

Description: Blood sampling for peripheral inflammatory and neurotoxicity markers

Type: Biological

Healthy controls Schizophrenia patients


Primary Outcomes

Description: Regional distribution volume in tissue (VT) of 2-(6-chloro-2-(4-(3-fluoropropoxy)phenyl)imidazo(1,2-a)pyridin-3-yl)-N,N-diethylacetamide (PBR111) labelled with fluorine-18 (18F) in schizophrenia patients and age- , gender-, and translocator protein (TSPO) binding profile- matched healthy controls

Measure: Regional VT of [18F]PBR111

Time: 2 years

Secondary Outcomes

Description: Levels and ratios of inflammatory and neurotoxicity markers in blood samples of schizophrenia patients compared to healthy age- and gender-matched healthy controls.

Measure: Peripheral markers

Time: 2 years

Time Perspective: Prospective

Case-Control


There is one SNP

SNPs


1 rs6971

- Low affinity binder of the TSPO, as determined by rs6971 polymorphism genotyping at Screening - Use of benzodiazepines for 3x the half-life prior to PET-scan - Presence of irremovable magnetic materials in or on the body - Has a medical history of organic brain disease - Has a medical history of traumatic brain injury - Has a medical history of allergic reaction to any of the substances in the tracer fluid.



HPO Nodes


HPO:
Psychosis
Genes 94
NPC1 NHLRC1 MKRN3 SNORD115-1 CACNA1A SLC12A6 CLN8 TMEM106B USP8 PRDM8 EPM2A MAGEL2 PANK2 PSEN1 COX1 COX2 COX3 ACADS PDGFB PDGFRB MAPT ZDHHC9 ATXN7 WFS1 SOBP SQSTM1 SLC20A2 CLN3 PARK7 RPS6KA3 PCDH19 ND1 TBC1D7 ND4 ND5 SLC6A19 ND6 PAH VPS13A NPAP1 TREM2 DCAF17 IPW PRKAR1A PWRN1 PAK3 SPART ALDH18A1 CDH23 HMBS TWNK TRNF ZFYVE26 GRN NPC2 ALAD TRNH NDN NDP UPF3B ABCD1 TRNL1 AIP GNAS PWAR1 HERC2 TRNQ TRNS1 TRNS2 C9ORF72 SLC7A7 TRNW ITM2B ATP13A2 CBS ALDH5A1 MECP2 LMBRD1 KCNT1 SNRPN MED12 SH2B1 SNORD116-1 NAGS PRNP MYORG TTC19 VCP GSS CHMP2B DNMT1 PPOX PDE11A MKRN3-AS1
Schizophrenia
Genes 50
WHRN FLI1 GJA5 GJA8 DNAJC13 CIB2 ARSA PSAP COMT SEC24C CEP78 ARVCF MYO7A ZDHHC9 WFS1 USH1G KRT81 DISC2 KRT83 KRT86 VPS35 UFD1 EIF4G1 LRRK2 PCDH15 GBA CDH23 GIGYF2 TRNE PDZD7 DSG4 UPF3B ADGRV1 HARS SNCA TRNS2 RREB1 USH1C USH2A ATP2A2 CLRN1 JMJD1C MED12 MSTO1 CHRNA7 TBX1 ARSG PRODH HIRA GP1BB